Yasmin




























Based upon presently available details on Yasmin, DRSP-containing COCs might be linked with a greater risk of venous thromboembolism (VTE) than COCs having the progestin levonorgestrel or a few other progestins. Epidemiologic studies that compared the threat of VTE stated that the threat varied from no boost to a three-fold increase. Before initiating usage of Yasmin in a brand-new COC customer or a woman that is switching from a contraceptive that does not have DRSP, consider the dangers and also advantages of a DRSP-containing COC taking into account her risk of a VTE. Known risk factors for VTE consist of family, smoking cigarettes, and obesity history of VTE, along with other aspects that contraindicate usage of COCs [see Contraindications (4)]



A number of researches have compared the risk of VTE for customers of Yasmin to the threat for individuals of other COCs, including COCs including levonorgestrel. Those that were needed or sponsored by regulative agencies are summed up in Table 1.



In addition to these "governing studies," other studies of various styles have actually been performed. On the whole, there are two possible mate research studies (see Table 1): the US post-approval security study Ingenix [Seeger 2007], the European post-approval safety research EURAS (European Active Surveillance Study) [Dinger 2007] An extension of the EURAS study, the Long-Term Active Surveillance Study (LASS), did not enroll added topics, however remained to analyze VTE danger. There are 3 retrospective mate studies: one research in the United States moneyed by the FDA (view Table 1), and two from Denmark [Lidegaard 2009, Lidegaard 2011] There are 2 case-control studies: the Dutch MEGA research evaluation [van Hylckama Vlieg 2009] and the German case-control study [Dinger 2010] There are 2 nested case-control studies that examined the threat of non-fatal idiopathic VTE: the PharMetrics research study [Jick 2011] and the GPRD study [Parkin 2011] The results of all these researches exist in Figure 1.